Primary Cutaneous B-cell Lymphoma Leg-type Related to a Tumour Necrosis Factor Alpha Inhibitor

Authors

  • Samy Belkaïd Centre Hospitalier de Valence, Service de dermatologie, Valence, France
  • Brigitte Balme 2. Hospices Civils de Lyon, Hôpital Lyon Sud, Service d’anatomie-pathologie, Pierre-Bénite, France
  • Olivier Harou 2. Hospices Civils de Lyon, Hôpital Lyon Sud, Service d’anatomie-pathologie, Pierre-Bénite, France
  • Joann Le Borgne de la Villandré Centre Hospitalier de Valence, Service de dermatologie, Valence, France
  • Chloé Wirbel Centre Hospitalier de Valence, Service de dermatologie, Valence, France
  • Stéphane Dalle Hospices Civils de Lyon, Hôpital Lyon Sud, Service de dermatologie, Pierre-Bénite, France
  • Florent Grange Centre Hospitalier de Valence, Service de dermatologie, Valence, France

DOI:

https://doi.org/10.2340/actadv.v102.348

Keywords:

TNF-alpha inhibitors, adalimumab, primary cutaneous B-cell lymphoma, PCBCL-LT

Abstract

Abstract is missing (Short communication)

Downloads

Download data is not yet available.

References

Lakatos PL, Miheller P. Is there an increased risk of lymphoma and malignancies under anti-TNF therapy in IBD? Curr Drug Targets 2010; 11: 179-186.

https://doi.org/10.2174/138945010790309867 DOI: https://doi.org/10.2174/138945010790309867

Hruska CJ, Bertoli RJ, Young YD, Burkhart PH, Googe PB. Primary cutaneous anaplastic large cell lymphoma in a patient receiving adalimumab. JAAD Case Rep 2015; 1: 56-59.

https://doi.org/10.1016/j.jdcr.2014.12.006 DOI: https://doi.org/10.1016/j.jdcr.2014.12.006

Martinez-Escala ME, Posligua AL, Wickless H, Rutherford A, Sable KA, Rubio-Gonzalez B, et al. Progression of undiagnosed cutaneous lymphoma after anti-tumor necrosis factor-alpha therapy. J Am Acad Dermatol 2018; 78: 1068-1076.

https://doi.org/10.1016/j.jaad.2017.12.068 DOI: https://doi.org/10.1016/j.jaad.2017.12.068

Muller M, D'Amico F, Bonovas S, Danese S, Peyrin-Biroulet L. TNF Inhibitors and risk of malignancy in patients with inflammatory bowel diseases: a systematic review. J Crohns Colitis 2021; 15: 840-859.

https://doi.org/10.1093/ecco-jcc/jjaa186 DOI: https://doi.org/10.1093/ecco-jcc/jjaa186

Maxwell LJ, Zochling J, Boonen A, Singh JA, Veras MM, Ghogomu ET, et al. TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev 2015; 4: CD005468.

https://doi.org/10.1002/14651858.CD005468.pub2 DOI: https://doi.org/10.1002/14651858.CD005468.pub2

Grange F, Beylot-Barry M, Courville P, Maubec E, Bagot M, Vergier B, et al. Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases. Arch Dermatol 2007; 143: 1144-1150.

https://doi.org/10.1001/archderm.143.9.1144 DOI: https://doi.org/10.1001/archderm.143.9.1144

Grange F, Joly P, Barbe C, Bagot M, Dalle S, Ingen-Housz-Oro S, et al. Improvement of survival in patients with primary cutaneous diffuse large B-cell lymphoma, leg type, in France. JAMA Dermatol 2014; 150: 535-541.

https://doi.org/10.1001/jamadermatol.2013.7452 DOI: https://doi.org/10.1001/jamadermatol.2013.7452

Graham PM, Richardson AS, Schapiro BL, Saunders MD, Stewart DM. Spontaneous regression of primary cutaneous diffuse large B-cell lymphoma, leg type with significant T-cell immune response. JAAD Case Rep 2018; 4: 305-309.

https://doi.org/10.1016/j.jdcr.2017.10.012 DOI: https://doi.org/10.1016/j.jdcr.2017.10.012

Zhao J, Han B, Shen T, Zhao Y, Wang T, Liu Y, et al. Primary cutaneous diffuse large B-cell lymphoma (leg type) after renal allograft: case report and review of the literature. Int J Hematol 2009; 89: 113-117.

https://doi.org/10.1007/s12185-008-0201-5 DOI: https://doi.org/10.1007/s12185-008-0201-5

Koens L, Senff NJ, Vermeer MH, Willemze R, Jansen PM. Methotrexate-associated B-cell lymphoproliferative disorders presenting in the skin: a clinicopathologic and immunophenotypical study of 10 cases. Am J Surg Pathol 2014; 38: 999-1006.

https://doi.org/10.1097/PAS.0000000000000225 DOI: https://doi.org/10.1097/PAS.0000000000000225

Pham-Ledard A, Beylot-Barry M, Barbe C, Leduc M, Petrella T, Vergier B, et al. High frequency and clinical prognostic value of MYD88 L265P mutation in primary cutaneous diffuse large B-cell lymphoma, leg-type. JAMA Dermatol 2014; 150: 1173-1179.

https://doi.org/10.1001/jamadermatol.2014.821 DOI: https://doi.org/10.1001/jamadermatol.2014.821

Downloads

Published

2022-04-04

How to Cite

Belkaïd, S., Balme, B., Harou, O., Le Borgne de la Villandré, J., Wirbel, C., Dalle, S., & Grange, F. (2022). Primary Cutaneous B-cell Lymphoma Leg-type Related to a Tumour Necrosis Factor Alpha Inhibitor. Acta Dermato-Venereologica, 102, adv00688. https://doi.org/10.2340/actadv.v102.348

Issue

Vol. 102 (2022)

Section

Short Communication

Categories

License

Copyright (c) 2022 Samy Belkaïd, Brigitte Balme, Olivier Harou, Joann Le Borgne de la Villandré, Chloé Wirbel, Stéphane Dalle, Florent Grange

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.

Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.

Crossref
Scopus
Google Scholar
Europe PMC